Self-assembling peptides repair damaged tight junctions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are insufficient for conditions characterized by fluid leakage and damage to tight junctions between cells, leading to disorders such as sepsis, inflammatory bowel disease, and postoperative seromas, which result in organ dysfunction and complications like dehydration and electrolyte imbalances.
Innovation Solution
Self-assembling peptides and peptidomimetics with alternating hydrophobic and hydrophilic residues that interact with the extracellular matrix to anchor and repair damaged tissue, forming structures that enhance the extracellular matrix and promote healing without causing secondary toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for leaky tight junctions and damaged tissue, then standard care is provided, but fluid leakage persists and tissue repair is insufficient
Solution Approach 1:
The patent introduces self-assembling peptides as intermediary materials that bridge damaged tissue edges and interact with the extracellular matrix. These peptides serve as mediators between the damaged tissue and the healing process, providing structural support and facilitating repair where conventional treatments fail to address the underlying matrix damage.
Solution Approach 2:
The invention changes the physical and chemical parameters of the treatment by using amphiphilic peptides with specific hydrophobic and hydrophilic residues that self-assemble into structured materials. This parameter change allows the material to interact specifically with the extracellular matrix and tight junctions, addressing the root cause of leakage rather than just managing symptoms.
2Productivity
If self-assembling peptides are applied to damaged tissue, then tissue repair is enhanced and hemostasis is accelerated, but the complexity of the treatment increases
Solution Approach 1:
The self-assembling peptides automatically organize themselves into structured materials when applied to damaged tissue, eliminating the need for complex application procedures or additional processing steps. The material performs self-assembly and self-integration with the extracellular matrix, reducing treatment complexity while maintaining high productivity in hemostasis and tissue repair.
3Object-affected harmful factors
If current treatments are used for postoperative seromas and leaky gut conditions, then standard management is provided, but complications such as infections and organ dysfunction occur
Solution Approach 1:
The self-assembling peptide material provides preemptive protection by reinforcing the extracellular matrix and sealing tight junctions before infections or organ dysfunction can develop. The material creates a protective barrier that prevents bacterial translocation in leaky gut conditions and prevents seroma formation after surgery, addressing potential complications before they occur.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These materials effectively anchor to tissue edges, accelerate hemostasis, and enhance tissue repair, reducing fluid leakage and promoting healing in damaged tissues, as demonstrated by rapid hemostasis in treated subjects compared to controls.
Implementation Method 1
Self assembling peptides and peptidomimetics with alternating hydrophobic and hydrophilic residues that interact with the extracellular matrix to anchor and repair damaged tissue
Implementation Method 2
peptides with alternating hydrophobic and hydrophilic residues that interact with the extracellular matrix
Data Source
AI summary
Self assembling peptides and peptidomimetics can be utilized for the treatment and support of disorders associated with leaky or damaged tight junction and weak, diseased, or injured extracellular matrix. The self-assembling materials generally have alternating hydrophilic or hydrophobic residues or hydrophobic and/or hydrophilic sections which allow the material to react or interact with the glycoproteins found in the ECM. Diseases in which treatment with these materials applied to or near the site in need of treatment include diabetic retinopathy, sepsis, burns, and certain neurodegenerative diseases such as Parkinson's and Alzheimer's. The formulations can be administered by injection, spraying, topically or by catheter or via a wound dressing or other material to which it is applied and then applied to the site in need of treatment.